SEC Form 4 · accession 0001209191-17-002211
Vanda Pharmaceuticals Inc. · VNDA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gian Piero Reverberi
Officer — SVP & Chief Commercial Officer
Period of report
Jan 3, 2017
Accepted (ET)
Jan 5, 2017 · 5:04 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001347178
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jan 3, 2017 | M | 12,500 | — | A | 12,500 | D | |
| Common StockF1 | Jan 3, 2017 | M | 7,500 | — | A | 20,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitF1,F2,F3 | — | Jan 3, 2017 | M | 12,500 | A | — | — | Common Stock | 12,500 | 37,500 | D |
| Restricted Stock UnitF1,F2,F3 | — | Jan 3, 2017 | M | 7,500 | A | — | — | Common Stock | 7,500 | 22,500 | D |
Explanation of responses
- F1Each Restricted Stock Unit ("RSU") represents a contingent right to receive a share of the Issuer's common stock.
- F2The RSUs shall vest in four (4) equal annual installments beginning January 1, 2017, provided Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest.
- F3Not Applicable.